Coronavirus | Novavax claims 90% efficacy for its vaccine

The company’s study involved nearly 30,000 persons aged 18 and above in the U.S. and Mexico.

Vaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said. While demand for COVID-19 shots in the U.S. has dropped dramatically, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies in the developing world.